Research Article
Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab
Table 3
EDSS score at 2 years in patients with optimal (0 relapse) or suboptimal responses (≥1 relapses) at 1 year—ITT population.
| ||||||||||||||||||||||||||||||||||||
a: value is from Wilcoxon rank sum test. |